Judge overturns Amgen’s $50m damages loss

A pair of patents behind an infringement case that proved expensive for Amgen have been found “unenforceable due to inequitable conduct”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS blocks biosimilar version of blockbuster cancer drug in India

21 July 2025 Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026.

Americas

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

2 July 2025 Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.

Americas

Regeneron hits Amgen over its blockbuster eye disease treatment

19 June 2025 The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.

More features

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

Why AI is changing the patent rules faster than anyone can keep up

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Judge overturns Amgen’s $50m damages loss

More on this story

Editor's picks

Editor's picks

More features